Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-30
2011-08-30
Noakes, Suzanne M. (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C436S004000
Reexamination Certificate
active
08008447
ABSTRACT:
The present disclosure concerns methods of crystallization and/or concentration of antibody or antibody fragments. The methods comprise contacting an antibody or antibody fragment with a solution comprising a salt of a divalent cation. Crystals and/or protein gels of antibody or antibody fragments are useful in compositions and formulations.
REFERENCES:
patent: 5608038 (1997-03-01), Eibl et al.
patent: 2004/0006208 (2004-01-01), Karpusas et al.
patent: 2004/0133357 (2004-07-01), Zhong et al.
patent: WO 91/09943 (1991-07-01), None
patent: WO 99/55310 (1999-11-01), None
patent: WO 02/30463 (2002-04-01), None
patent: WO 02/072636 (2002-09-01), None
patent: WO 2004/091658 (2004-11-01), None
Stura et al. Acta Crystallographica Section D. Oct. 2002, part 1, D58:1740-43.
Cho et al Nature, 2003, 421:756-7601.
Nguyen et al. Nature Structure Biology, 2003, 10(12):1019-25.
Ahamed et al. “Phase Behaviour of Intact Monoclonal Antibody”, Biochemical Journal, Jul. 2007, vol. 93, pp. 610-619.
Navia et al. “Crystal structure of galactan-binding mouse immunoglobulin J539 Fab at 4.5-Å resoluction.”Proc. Natl. Acad. Sci. USA. vol. 76, No. 8. Aug. 1979. pp. 4071-4074.
Huang et al. “Three quaternary structures for a single protein.”Proc. Natl. Acad. Sci. USA. vol. 93. Jul. 1996. pp. 7017-7021.
Chang et al. “Novel Arrangement of Immunoglobulin Variable Domains: X-ray Crystallographic Analysis of the λ-Chain Dimer Bence-Jones Protein Loc.”Biochemistryvol. 24. 1985. pp. 4890-4897.
Yang et al. “Crystalline monoclonal antibodies for subcutaneous delivery.”PNAS. vol. 100, No. 12. Jun. 10, 2003. pp. 6934-6939.
Cudney et al. “Screening and Optimization Strategies for Macromolecular Crystal Growth.”Acta Crystallographica Section D. vol. 50. 1994. pp. 414-423.
Harris et al. “Crystallization of Intact Monoclonal Antibodies.”Proteins: Structure, Function, and Genetics. vol. 13. 1995. pp. 285-289.
Stura et al. “Reverse Screening.”Acta Crysallographica Section D. vol. 50. 1994. pp. 448-455.
Muller et al. “VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4. Å resolution and mutational analysis of the interface.”Structure. vol. 6, No. 9. 1998. pp. 1153-1167.
Chen et al. “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen.”J. Mol. Biol. vol. 293, No. 4. 1999. pp. 865-881.
Ferrara et al. “Discovery and Development of Bevacizumab, an Anti-VEGF antibody for treating cancer.”Nature Reviews: Drug Discovery. vol. 3. May 2004. pp. 391-400.
Cleland et al. “The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation.”Crit. Rev. in Thera. Drug Carrier Systems. vol. 10, No. 4. 1993. pp. 307-377.
Cromwell Mary E. M.
Dinges Rachel Bulotsky
Fukami Julie
Hagewiesche Annette Marie Clasen
Arnold & Porter LLP
De Vry Christopher
Genentech Inc.
Noakes Suzanne M.
Pleasure Irene
LandOfFree
Crystallization of antibody or fragment thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystallization of antibody or fragment thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystallization of antibody or fragment thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659548